Aberdeen Group’s TScan Therapeutics TCRX Stock Holding History

Aberdeen Group’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-918,020	Closed	-$927K	–	972
2026 Q1	$927K	Sell	918,020 -867,221	-49%	-$927K	﹤0.01%	829
2025 Q4	$1.79M	Buy	1,785,241 +430,421	+32%	+$623K	﹤0.01%	787
2025 Q3	$2.47M	Buy	1,354,820 +463,372	+52%	+$821K	﹤0.01%	763
2025 Q2	$1.29M	Hold	891,448	–	–	﹤0.01%	810
2025 Q1	$1.23M	Buy	891,448 +7,744	+0.9%	+$16.8K	﹤0.01%	800
2024 Q4	$2.69M	Buy	883,704 +512,049	+138%	+$2.32M	0.01%	729
2024 Q3	$1.85M	Buy	371,655 +79,511	+27%	+$480K	﹤0.01%	760
2024 Q2	$1.71M	Buy	292,144 +92,144	+46%	+$726K	﹤0.01%	769
2024 Q1	$1.59M	Hold	200,000	–	–	﹤0.01%	793
2023 Q4	$1.17M	Buy	+200,000	New	+$916K	﹤0.01%	825

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Aberdeen Group's TCRX Position: Q2 2026 in Review

Aberdeen Group sold out of TScan Therapeutics (TCRX) in Q2 2026, closing a stake of 918,020 shares — an estimated $927K sold.

Aberdeen Group first reported a position in TCRX in Q4 2023 and held it in 10 quarters. The position peaked at $2.69M in Q4 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

Aberdeen Group reported no remaining TScan Therapeutics position as of Q2 2026 after selling out during the quarter.
Aberdeen Group sold 918,020 TScan Therapeutics shares in Q2 2026, an estimated $927K.
Aberdeen Group first reported a position in TScan Therapeutics in Q4 2023 and held it in 10 quarters.
Aberdeen Group's TScan Therapeutics position peaked at $2.69M in Q4 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.